Sumatriptan CAS #: 103628-46-2 Sumatriptan is an API that works with the serotonin neurons in the brain to fight migraines and cluster headaches. By constricting the blood vessels in the brain back to their normal size and preventing the trigeminal nerve from firing at full force, sumatriptan is designed to stop symptoms as soon as they start.[…]
Sumatriptan: An Effective Choice to Fight Migraines and Cluster Headaches
Anti-Migraine, Compounding API Tags: migrainesserotonin Dec 28, 2018
Almotriptan Patent to Expire in May 2015
Anti-Migraine, Drug Research & Development API, Patent Expiration 2015 Tags: migraine headachesserotonin May 05, 2015
Known as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults[…]
FDA Agrees to Priority Review of Sumatriptan and Naproxen Sodium for Adolescent Patients
Anti-Migraine, Drug Research & Development API, FDA Priority Status, OTC and Compounding Product Tags: migraine headachesmigraines Apr 15, 2015
On January 15, 2015 Pernix Therapeutics excitedly announced an FDA acceptance for a priority review of Sumatriptan and Naproxen Sodium, also known as Treximet, for adolescent patients. Pernix expects an FDA approval by the second quarter of 2015, which would greatly benefit the adolescent patient population suffering from migraines. This anticipated approval would be specific[…]
Rizatriptan Gets FDA Nod as New Generic for Migraine Therapy
Anti-Inflammatory, Anti-Migraine, FDA Approved 2015 Tags: migraine headachesmigrainesserotoninUnited States Mar 12, 2015
On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]
FDA Accepts NDA for Novel Intranasal Sumatriptan to Treat Migraines
Anti-Migraine, Drug Research & Development API Tags: migraine headachesmigrainesNew Drug Application Apr 24, 2014
Exciting news was disseminated from Avanir Pharmaceuticals’ on March 28, 2014 with their announcement that the FDA had accepted a New Drug Application for their intranasal form of Sumatriptan. Designed as a novel and investigational drug-device combination product coined AVP-825, this unique form of Sumatriptan is a breath powered, intranasal form of migraine treatment. The[…]
Propranolol Hydrochloride U.S. & E.U. Approved to Treat Infantile Hemangioma
Anti-Migraine, Drug Research & Development API, EU Approved 2014, FDA Approved 2014 Tags: EU Mar 28, 2014
UPDATE: On May 6, 2014, Propranolol was approved by the European Commission for treatment of infantile hemangioma. Infantile hemangioma, or an overgrowth of blood vessels on or under the skin of infants is a benign vascular condition. As a common non-life threatening tumor of the skin, infantile hemangioma occur during the first four weeks of[…]
Topiramate Approved as Antiepileptic Drug
Anti-Migraine, Anti-Obesity Product, FDA Approved 2014 Tags: Annual MeetingepilepsyTopiramate Mar 14, 2014
On March 11, 2014 the FDA approved Topiramate, marketed as Qudexy™ XR by Upsher-Smith Laboratories, for the treatment of partial-onset seizures (POS) or primary generalized tonic-clonic seizures in patients 10+ years of age. It is also approved as adjunctive therapy in patients 2+ years of age for the aforementioned seizures, and seizures associated with Lennox-Gastaut[…]
New Guidelines Highlight Divalproex Sodium as an Effective Migraine Treatment
Anti-Migraine, Patent Expiration 2018 Tags: migraine headachesWorld Health Organization May 20, 2013
The latest news regarding divalproex sodium is exciting for patients who suffer from migraine headaches. A new set of guidelines were published in the April 24, 2012 issue of Neurology, and presented at the academy’s annual meeting in New Orleans April 21 to 28, 2013. The new guidelines are composed of information from 29 studies[…]
Migraine Sufferers Find Relief with Eletriptan Hydrobromide
Anti-Migraine, Drug Research & Development API, Patent Expiration 2016 Tags: migrainesPfizerWorld Health Organization Jan 09, 2013
Eletriptan Hydrobromide, CAS number 143322-58-1, is a medication indicated for the acute treatment of migraine with or without aura in adults. Known as Relpax, which is marketed by Pfizer, the patent expiration for Eletriptan Hydrobromide is on December 26, 2016 (Patent Use Code U – 876 – TREATMENT OF MIGRAINE WITH OR WITHOUT AURA). Available in[…]
Topiramate Works for Patients with Epilepsy and Migraines
Anti-Migraine, Anti-Obesity Product, Drug Research & Development API, Patent Expiration 2015 Tags: epilepsymigrainesTopiramate Aug 07, 2012
Topiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets[…]
- 1
- 2
